Navigation Links
Orexigen Announces Successful Interim Analysis of Contrave Light Study
Date:11/25/2013

SAN DIEGO, Nov. 25, 2013 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced successful results of the interim analysis of the Light Study. Based on these results, the Company will resubmit the Contrave® New Drug Application (NDA) to the United States Food and Drug Administration (FDA) in the next few weeks with potential approval by June 2014. 

"The interim analysis of the Light Study clearly achieved the goal set by the FDA," said Michael Narachi, CEO of Orexigen.  "The resubmission will contain an unprecedented amount of cardiovascular outcomes data for an obesity therapeutic, and we are confident these data will support a favorable benefit:risk assessment for Contrave."

The FDA previously agreed that if the interim analysis meets the specified criteria to exclude cardiovascular risk, Contrave could be approved. The pre-specified criteria for the interim analysis is to exclude a hazard ratio of 2.0, using the upper bound of the 95% confidence interval, for excess risk of major adverse cardiovascular events (MACE) in patients receiving Contrave as compared to placebo. In addition to meeting the pre-specified criteria for excluding cardiovascular risk, no new safety signals were observed.

"Takeda is excited about this major milestone for Contrave," said Doug Cole, President of Takeda Pharmaceuticals U.S.A., Inc., Orexigen's partner for Contrave in North America. "Takeda is pleased to partner with Orexigen to develop a therapeutic option that has the potential to help patients achieve meaningful and sustained weight loss over time."

Conference Call This Morning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) The Orexigen management team will host a teleconference and webcast to d
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Nuclear medicine market is estimated to ... Nuclear are drugs that contain radionuclide-emitting ionization radiation, ... and treat diseases. Increasing incidences of ... and ready availability of radiopharmaceuticals are the major ... awareness and use of SPECT and PET also ...
(Date:9/23/2014)...  SI-BONE, Inc., a medical device company that pioneered ... a minimally invasive surgical (MIS) device indicated for fusion ... U.S. Patent and Trademark Office has awarded the company ... fixation and fusion of bone.  This newly issued patent ... may be placed from one bone across a joint ...
(Date:9/23/2014)... , Sept. 23, 2014   LabStyle Innovations ... Diabetes Management Solution, today announced that it has ... of shares of preferred stock and warrants.  No ... estimated offering expenses, LabStyle expects to secure net ... LabStyle intends to use the ...
Breaking Medicine Technology:Global Nuclear Medicine Market - Growth, Trends & Forecasts (2014-2019) 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5
... Use of,a low profile PressureWire yields a ... to catheter-derived pressure gradient,(CPG) measurements, according to a ... Vol. 20, Issue 1: 63-65)., The authors ... a,catheter and PressureWire correlated with anatomic stenosis, PressureWire,gradient ...
... 27 Puroast(R) Low Acid Coffee,has conducted both ... its great tasting, gourmet coffee provides symptom relief ... brew. Puroast(R) achieves,this without extractions, substitutes or additives; ... full-bodied taste., Prior chemistry research at University ...
Cached Medicine Technology:Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 2Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 3Low Acid Coffee Backed By Scientific Research 2
(Date:9/23/2014)... (September 23, 2014) Both patients and healthcare ... computed tomography (CT) colonography greatly outweighs the potential ... precipitated by false-positive diagnoses, according to a new ... journal Radiology . , Diagnostic tests used ... organ. However, when screening for colorectal cancer with ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Trevera ... services market. Included are Oracle Managed Services ... Trevera supports all versions of Oracle E-Business Databases ... releases. , Trevera has announced a significant ... that need help with their software technology management, ...
(Date:9/23/2014)... September 23, 2014 The Sloane ... in Singapore and Malaysia providing advanced aesthetic dermatology ... powder to its impressive skin care repertoire. Specially ... skin’s defences against the evil forces of aging, ... glow simultaneously, this new addition is revolutionizing the ...
(Date:9/23/2014)... NC (PRWEB) September 23, 2014 ... a national research university located In the Piedmont ... joined UNCG as co-director of the Center for ... bioanalytical chemistry, comes to UNCG after nearly a ... Northwest National Laboratory, Biological Sciences Division. , ...
(Date:9/23/2014)... HealthDay Reporter MONDAY, ... marches demanding action on climate change, a new study ... the United States may soon exacerbate many existing health ... illnesses are expected to increase as the number of ... Patz, director of the Global Health Institute at the ...
Breaking Medicine News(10 mins):Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3Health News:Trevera, Inc adds Management Support to Services 2Health News:Trevera, Inc adds Management Support to Services 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 3
... development of autism in infants, comparing the behavior of the ... developing normally, has found that the nascent symptoms of the ... communicative babbling are not present at 6 months, but ... of the first year of life. Researchers conducted the ...
... have identified a mechanism used by the tuberculosis bacterium ... a compound that blocks the bacterium,s ability to survive ... to treat tuberculosis. Zhong-Yin Zhang, Ph.D., Robert A. ... and Molecular Biology, and his colleagues revealed the biochemical ...
... , Feb. 15 In just two weeks, online ... helping the organization come in first with more than 49 percent ... the Super Love Sender giving campaign on the Target Facebook® page. ... on February 14, 2010 , invited the online community and ...
... (OHRI) and the University of Ottawa suggests that stem cells ... tissue development. The study, published in Proceedings of the ... researchers think about tissue development, stem cells and cancer. ... all our genes. Certain chemicals and UV light can break ...
... finds , MONDAY, Feb. 15 (HealthDay News) --People who think ... of cigarettes are kidding themselves, a new study shows. , ... Dr. R. Graham Barr, assistant professor of medicine and epidemiology ... report in the Feb. 16 issue of Annals of ...
... effect on squamous cell carcinoma , MONDAY, Feb. 15 ... of NSAID painkillers might help reduce cancer risk, a ... protection against a common skin cancer. , Previous research ... such over-the counter medications as Advil, Motrin, aspirin, Celebrex ...
Cached Medicine News:Health News:Autism's earliest symptoms not evident in children under 6 months 2Health News:Autism's earliest symptoms not evident in children under 6 months 3Health News:Autism's earliest symptoms not evident in children under 6 months 4Health News:IU research team discovers TB disease mechanism and molecule to block it 2Health News:Fans Spread the Love on Target Facebook Page and Help Donate $1 Million to Five Charities 2Health News:Fans Spread the Love on Target Facebook Page and Help Donate $1 Million to Five Charities 3Health News:Fans Spread the Love on Target Facebook Page and Help Donate $1 Million to Five Charities 4Health News:New study suggests stem cells sabotage their own DNA to produce new tissues 2Health News:Cigars, Pipes No 'Healthy' Alternative to Cigarettes 2Health News:Cigars, Pipes No 'Healthy' Alternative to Cigarettes 3Health News:NSAIDs Won't Shield Against Skin Cancer 2Health News:NSAIDs Won't Shield Against Skin Cancer 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: